Canada markets open in 6 hours 4 minutes
  • S&P/TSX

    21,216.15
    +3.75 (+0.02%)
     
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • DOW

    35,677.02
    +73.92 (+0.21%)
     
  • CAD/USD

    0.8099
    +0.0007 (+0.09%)
     
  • CRUDE OIL

    84.39
    +0.63 (+0.75%)
     
  • BTC-CAD

    77,191.30
    +1,637.86 (+2.17%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • GOLD FUTURES

    1,799.20
    +2.90 (+0.16%)
     
  • RUSSELL 2000

    2,291.27
    -4.91 (-0.21%)
     
  • 10-Yr Bond

    1.6550
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,368.25
    +27.25 (+0.18%)
     
  • VOLATILITY

    15.43
    +0.42 (+2.80%)
     
  • FTSE

    7,226.51
    +21.96 (+0.30%)
     
  • NIKKEI 225

    28,600.41
    -204.44 (-0.71%)
     
  • CAD/EUR

    0.6948
    +0.0006 (+0.09%)
     

Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Tilray, Inc. (TLRY) closed at $12.17 in the latest trading session, marking a +1.33% move from the prior day. This move outpaced the S&P 500's daily loss of 0.91%.

Coming into today, shares of the company had lost 5.28% in the past month. In that same time, the Medical sector lost 0.52%, while the S&P 500 gained 0.01%.

TLRY will be looking to display strength as it nears its next earnings release.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.14 per share and revenue of $785.29 million, which would represent changes of +69.57% and +166.34%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for TLRY. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. TLRY is holding a Zacks Rank of #3 (Hold) right now.

The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 197, which puts it in the bottom 23% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Tilray, Inc. (TLRY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting